A Multicenter, Vehicle-controlled, Double-Masked, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

Unknown Phase 1,Phase 2 NCT04030962

Study Description

This was a 2-stage study in which Stage 1 evaluated the safety of AGN-242428 and AGN-231868, how well they are tolerated, and how they move through the body when administered. After the sponsor's determination of adequate safety and tolerability of the interventions in Stage 1, Stage 2 began. Stage 2 also evaluated the safety and tolerability of AGN-242428 and AGN-231868, how effective they are in treating dry eye disease (DED), and assessed the plasma and tear exposure of both ophthalmic solutions.

Study Details

Registry ID:
NCT04030962
Conditions:
Dry Eye Disease, Dry Eye Syndrome
Phase:
Phase 1,Phase 2
Target Enrollment:
292 participants
Start Date:
Age Range:
18–999 years
Healthy Volunteers:
No

Study Locations (12 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →